20:19 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Bionomics discontinues BNC210 for PTSD after Phase II miss

Bionomics Ltd. (ASX:BNO; OTCQX;BNOEF) discontinued development of BNC210 to treat posttraumatic stress disorder (PTSD) after the compound missed the primary endpoint in the Phase II RESTORE trial in the indication. Twice-daily oral BNC210 did not...
16:06 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Oyster Point's OC-02 nasal spray meets in Phase IIb for dry eye

Oyster Point Pharma Inc. (Princeton, N.J.) said its OC-02 nasal spray met the primary endpoints in the double-blind, U.S. Phase IIb PEARL trial to treat dry eye disease. CEO Jeffrey Nau told BioCentury Oyster Point...
21:34 , Jul 12, 2018 |  BC Extra  |  Clinical News

Oyster Point's nasal spray meets in Phase IIb for dry eye

Oyster Point Pharma Inc. (Princeton, N.J.) said its OC-02 nasal spray met the primary endpoints in the U.S. Phase IIb PEARL trial to treat dry eye disease. CEO Jeffrey Nau told BioCentury Oyster Point plans...
15:37 , May 4, 2018 |  BC Week In Review  |  Financial News

Attenua raises $35M series A

Cough company Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round on April 30 in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and...
19:46 , Apr 30, 2018 |  BC Extra  |  Financial News

Cough company Attenua raises $35M series A, names CEO

Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and Redmile Group also participated. Attenua plans to start Phase II trials...
04:17 , Dec 8, 2017 |  BC Week In Review  |  Financial News

Axsome raises $9.5M in direct offering

CNS company Axsome Therapeutics Inc. (NASDAQ:AXSM) raised $9.5 million through the sale of 1.8 million units at $5.33 in a registered direct offering led by HC Wainwright. Each unit represents one share of common stock and...
19:50 , Aug 4, 2017 |  BC Week In Review  |  Clinical News

Axsome starts Ph III of AXS-05 to treat agitation in AD patients

Axsome Therapeutics Inc. (NASDAQ:AXSM) began the Phase II/III ADVANCE-1 trial of AXS-05 to treat agitation in patients with Alzheimer's disease. The double-blind, U.S. trial will enroll about 435 patients to receive placebo, bupropion or oral...
20:08 , Apr 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection Patient sample and mouse studies suggest inhibiting adrenergic receptors, PGR, cortisol receptor GR-2 and/or CHRNB2 could help treat post-stroke Listeria monocytogenes infection. Post-stroke patients had lower numbers of circulating peripheral NK cells than...
20:15 , Feb 16, 2017 |  BC Week In Review  |  Company News

Bionomics, Merck deal

Bionomics will receive a $10 milestone payment from Merck under a 2014 deal granting the pharma exclusive, worldwide development and commercialization rights to Bionomics’ BNC375 program, which targets cognitive dysfunction associated with Alzheimer’s disease and...
20:03 , Dec 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Asthma Cell culture and mouse studies suggest CHRNA7 agonists could help treat allergic asthma. In a mouse model of airway hyperresponsiveness, intranasal administration of a CHRNA7 agonist tool compound decreased airway resistance and dynamic compliance,...